[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100403065":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":39,"centralContacts":43,"locations":52,"responsibleParty":87,"collaborators":90,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":102,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":10,"studyType":108,"phases":10,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Columbia University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BoneGN participants",null,"Participants who have already been recruited into the CureGN study, or meet its criteria.",[13,14,15,16],"Radiation: Dual-energy X-ray absorptiometry","Radiation: High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)","Other: Blood draw and Urine collection","Other: Questionnaires",[18,25,31,35],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"RADIATION","Dual-energy X-ray absorptiometry","DXA whole body, hip, spine, and radius at baseline, and 12-month visit.",[9],[24],"Bone density",{"type":19,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)","HR-pQCT of the radius and tibia at baseline, and 12-month visit.",[9],[30],"HR-pQCT",{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Blood draw and Urine collection","The blood draw can be completed +\u002F- 3 weeks from baseline or 12-month visit.",[9],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Questionnaires","Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.",[9],[40],{"name":41,"affiliation":5,"role":42},"Thomas L. Nickolas, MD","PRINCIPAL_INVESTIGATOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":10,"email":48},"Maria A. Aponte","CONTACT","(212) 342-4678","maa2308@cumc.columbia.edu",{"name":41,"role":46,"phone":50,"phoneExt":10,"email":51},"(212) 305-3273","tln2001@cumc.columbia.edu",[53,70],{"facility":54,"status":55,"city":56,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Columbia University Irving Medical Center","RECRUITING","New York","10032","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-74.00597,40.71427,{"lat":64,"lon":63},[67,69],{"name":45,"role":46,"phone":68,"phoneExt":10,"email":48},"212-342-4678",{"name":41,"role":42,"phone":10,"phoneExt":10,"email":10},{"facility":71,"status":55,"city":72,"state":73,"zip":74,"country":58,"countryCode":59,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"The Children's Hospital of Philadelphia","Philadelphia","Pennsylvania","19104",{"type":61,"coordinates":76},[77,78],-75.16362,39.95238,{"lat":78,"lon":77},[81,85],{"name":82,"role":46,"phone":83,"phoneExt":10,"email":84},"Erin Doherty","267-600-6233","dohertye@email.chop.edu",{"name":86,"role":42,"phone":10,"phoneExt":10,"email":10},"Michelle R. Denburg, MD",{"type":42,"investigatorFullName":88,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Thomas Nickolas, MD MS","Professor of Medicine",[91],{"name":92,"class":93},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100403065","the-impact-of-glomerular-disorders-on-bone-quality-and-strength-100403065",false,"NCT04528446","The Impact of Glomerular Disorders on Bone Quality and Strength","BoneGN","Inclusion Criteria for participants with glomerular disease:\n\n1. CureGN participant or CureGN Eligible\n\n   CureGN eligible is defined as having a diagnosis of Glomerulonephropathy (GN). Patients would otherwise be enrolled in be in CureGN study, except for lacking a minor entry criteria, such as:\n   1. First diagnostic kidney biopsy within 5 years of CureGN study enrollment\n   2. Access to first kidney biopsy report and\u002For slides or not being interested in study participation.\n2. Males or females 5 to 55 years (premenopausal for women)\n3. Females must have a negative urine\u002Fserum pregnancy test\n4. Stable doses of nutritional vitamin D or active vitamin D therapy for at least 3 months before enrollment ((if on either form of Vitamin D)\n5. Consent\u002FParental\u002Fguardian permission (informed consent) and if appropriate, child assent\n\nExclusion Criteria for all participants\n\n1. Chronic Dialysis\n2. Solid organ transplantation\n3. Lower extremity amputations or non-ambulatory\n4. Malignancy requiring chemotherapy or metastatic to bone\n5. Metabolic bone disease (e.g., Paget's disease, primary hyperparathyroidism)\n6. Endocrinopathy (current hyperthyroidism or untreated hypothyroidism, Cushing's syndrome)\n7. Medical diseases (end stage liver disease, heart or lung disease, intestinal malabsorption)\n8. Those treated with bisphosphonates, teriparatide, calcitonin, selective estrogen receptor modulators, estrogen, or phenytoin in the past 12 months\n9. Previous bilateral wrist and tibia fractures\n10. Pregnant or lactating females\n11. Parents\u002Fguardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.",true,"ALL","5 Years","55 Years",{"count":106,"type":107},270,"ESTIMATED","OBSERVATIONAL","The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.",[111,112,113],"Glomerular Disease","Bone Diseases, Metabolic","Bone Fracture",[115,113],"Kidney Disease","2024-06-28",{"date":118,"type":119},"2024-07-01","ACTUAL",{"date":121,"type":119},"2019-06-14",{"date":123,"type":107},"2024-12",{"name":5,"class":6},2]